7500 Volunteers Enrolled in REPRIEVE Study (A5322) of HIV and Heart Health

Full enrollment of the REPRIEVE study (Randomized Trial to Prevent Vascular Events in HIV, ACTG A5322) was commemorated in May with a NIAID Now blog and video. REPRIEVE opened in 2015 with support from NIAID and NHLBI. This ambitious trial is testing whether a statin medication can reduce the risk of heart disease in men and women with HIV who have low to moderate traditional risk factors for CVD. Participants are randomized to receive pitavastatin 4mg daily or placebo and will be followed for up to 8 years. Researchers completed the enrollment phase of the trial earlier this year, with more than 7,500 participants in eleven countries enrolled.

REPRIEVE investigators and NIAID collaborators also discussed the study design and goals in the June issue of the American Heart Journal (Grinspoon S et al. Rationale and Design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). American Heart Journal. June 2019; 212: 23-35). Congratulations to the REPRIEVE team on the successful enrollment of this important study!